Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, April 8, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities has updated their analysis of ExpreS2ion following the announcement that the Company will be conducting a Rights Issue. Pareto reiterated its `buy' rating and reduced its target price to SEK 86 per share after incorporating the estimated dilution from the Rights Issue.
The research report is available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se